English
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
iris/inflammation
The link is saved to the clipboard
Page 1 from 16 results
PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS)
Only registered users can translate articles
Log In/Sign up
1. FIELD
Provided herein are compositions and methods for the treatment of IRIS by administering to a patient in need thereof an effective amount of a PDE4 modulator described herein.
2. BACKGROUND
One goal of antiretroviral therapy (ART) in immunocompromised HIV-infected individuals is immune
Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
Only registered users can translate articles
Log In/Sign up
SEQUENCE LISTING SUBMISSION VIA EFS-WEB
A computer readable text file, entitled "067802-5030_SequenceListing.txt," created on or about 10 Apr. 2013, with a file size of about 62 kb contains the sequence listing for this application and is hereby incorporated by reference in its entirety.
The present
Compositions and methods for protecting the kidney from ischemia reperfusion injury
Only registered users can translate articles
Log In/Sign up
BACKGROUND
Renal ischemia-reperfusion injury (IRI) is a major cause of acute kidney injury (AKI) in many clinical settings including cardiovascular surgery, sepsis, and kidney transplantation. Ischemic AKI is associated with increased morbidity, mortality, and prolonged hospitalization (1, 2).
Acute
Polyoma virus JC peptides and proteins in vaccination and diagnostic applications
Only registered users can translate articles
Log In/Sign up
RELATED APPLICATIONS
This application is a 35 U.S.C. 371 national stage filing of International Application No. PCT/EP2012/064445, filed on Jul. 23, 2012, which claims priority to European Patent Application No. 11006031.6, filed on Jul. 22, 2011. The contents of the aforementioned applications are
Therapeutic CD47 antibodies
Only registered users can translate articles
Log In/Sign up
SEQUENCE LISTING
The present application is being filed along with a sequence listing in electronic format. The sequence listing is provided as a file entitled, "VLX0001-201-US 20131212 SequenceListing_ST25", created on Dec. 11, 2013 which is 90 Kb in size. The information in the electronic format
Therapeutic CD47 antibodies
Only registered users can translate articles
Log In/Sign up
SEQUENCE LISTING
The present application is being filed along with a sequence listing in electronic format. The sequence listing is provided as a file entitled, "VLX0001-201-US 20131212 SequenceListing_ST25", created on Dec. 11, 2013 which is 90 Kb in size. The information in the electronic format
Therapeutic CD47 antibodies
Only registered users can translate articles
Log In/Sign up
SEQUENCE LISTING
The present application is being filed along with a sequence listing in electronic format. The sequence listing is provided as a file entitled, "VLX0001-201-US 20131212 SequenceListing_ST25", created on Dec. 11, 2013 which is 90 Kb in size. The information in the electronic format
Therapeutic CD47 antibodies
Only registered users can translate articles
Log In/Sign up
The present invention relates to antibodies that bind CD47 and their use in treating conditions and disorders, such as ischemia-reperfusion injury (IRI) and cancers, mediated by this receptor.
CD47 is a cell surface receptor comprised of an extracellular IgV set domain, a 5 membrane spanning
Therapeutic CD47 antibodies
Only registered users can translate articles
Log In/Sign up
INCORPORATION OF SEQUENCE LISTING
The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled, "VLX0001-201CIP2 US_SequenceListing", created on Jun. 11, 2015, which is 168,755 bytes in size. The information in the
Therapeutic CD47 antibodies
Only registered users can translate articles
Log In/Sign up
BACKGROUND
The present disclosure relates to antibodies that bind CD47, including that of humans and other mammalian species, and their use in treating conditions and disorders, such as ischemia-reperfusion injury (IRI) and cancers, mediated by this receptor.
CD47 is a cell surface receptor
Cyclic compounds
Only registered users can translate articles
Log In/Sign up
TECHNICAL FIELD
The present invention relates to novel cyclic compounds having a Toll-like receptor 4 (TLR4) signal inhibitory action useful as preventive and therapeutic drugs of autoimmune disease and/or inflammatory disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN),
Cyclic compounds
Only registered users can translate articles
Log In/Sign up
TECHNICAL FIELD
The present invention relates to novel cyclic compounds having a Toll-like receptor 4 (TLR4) signal inhibitory action useful as preventive and therapeutic drugs of autoimmune disease and/or inflammatory disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN),
Rationale for IL-1 .beta. targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
Only registered users can translate articles
Log In/Sign up
BACKGROUND OF THE INVENTION
Ischemia-reperfusion injury (IRI) involving harvested organs and allograft transplantation may in part be caused by stimulation of a newly described innate pro-inflammatory immune system (i.e. cryopyrin-inflammasome, now referred to as NLRP-3 or NALP-3 inflammasome) that
Ultrapure hyaluronic acid and the use thereof
Only registered users can translate articles
Log In/Sign up
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to an ultrapure, high molecular weight hyaluronic acid, generally, but not necessarily in the form of the sodium salt (hereinafter referred to as "HUA"), obtained from animal connective tissue such as rooster combs, human
Non-primate vitreal replacement process
Only registered users can translate articles
Log In/Sign up
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention pertains to a non-primate vitreal replacement process that quantitates the inflammatory response to viscoelastic agents or solutions.
2. Description of the Prior Art
The owl monkey (Aotus trivigatus) was used as a process
The most complete medicinal herbs database backed by science
- Works in 55 languages
- Herbal cures backed by science
- Herbs recognition by image
- Interactive GPS map - tag herbs on location (coming soon)
- Read scientific publications related to your search
- Search medicinal herbs by their effects
- Organize your interests and stay up do date with the news research, clinical trials and patents
Type a symptom or a disease and read about herbs that might help, type a herb and see diseases and symptoms it is used against.
*All information is based on published scientific research
